Genomic Biomarkers Is a Measurable RNA or DNA Characteristics, Which Is an Indication of Therapeutic, Pathogenic, and Biologic Processes and Interventions

 

Genomic biomarkers are used all over the world, especially in regions such as the US, UK, and Italy. The use of genomic biomarkers in genetic studies has been widely employed to monitor gene function over the years. Genomic biomarkers have identified abnormal tissue growth or changes in a person's DNA resulting from environmental exposure such as smoking or alcohol abuse. These genetic changes can then be used to screen individuals for specific diseases and traits. In the past, these genetic studies relied on PCR-based approaches, which require amplifying DNA on living cells.

Recently, new technology has entered the field of molecular medicine due to its ability to provide unbiased results with less cost and better accuracy than other established genomics-based tests and procedures. Although more research is needed to confirm the effectiveness of genomic biomarkers, this technique may provide a useful tool for clinical settings. Here we discuss developments in this area that may prove to be of significant importance for drug discovery and therapeutic trial research. In regions such as the U.S., the increasing prevalence of biotechnology labs and companies has increased the research and developments of the genomic biomarker. For instance, according to Biotechnology Innovation Organization, there are over 449 biotechnology companies in the United States.

One of the main goals for clinical trials is the identification of compounds that can improve the effects of treatment. Although many compounds with proven activity are being developed, it may be difficult to identify which among them are the candidates for human clinical trials. The challenge in this area is identifying genetic events that occur in individual patients and which therefore affect their response to treatment. Genomic biomarkers can help researchers address this problem by revealing whether the genetic event was the primary driver of the observed changes in behavior or whether the observed changes are due to other environmental factors. Genomic biomarker allows researchers to efficiently evaluate and select drugs based on their ability to alter biological pathways affected by the disorder.

Another important aim of drug development is the development of genetically diverse, pharmacological agents capable of combating numerous health problems. Although traditional genetic approaches have yielded promising results in this area, they have had less impact on areas such as Alzheimer's disease and obesity. Because genomic biomarkers are usually unique to a particular individual, it may be challenging to determine if the markers used are reliable predictors of these diseases.